Cell Signaling Technology Logo
View Featured Offers >>
1% for the planet logo
  1. Products /
  2. Primary Antibodies /
  3. Lipid Metabolism/Ferroptosis Antibody Sampler Kit

Lipid Metabolism/Ferroptosis Antibody Sampler Kit #58434

    Product Information

    Kit Usage Information

    Protocols

    Product Description

    The Lipid Metabolism/Ferroptosis Antibody Sampler Kit provides an economical means of detecting select components involved in lipid metabolism and ferroptosis. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.

    Background

    Mammalian long-chain acyl-CoA synthetase (ACSL) catalyzes the ligation of the fatty acid to CoA to form fatty acyl-CoA in a two-step reaction. Five isoforms of ACSL have been identified (1). Overexpression of ACSL1 results in changes to fatty acid metabolism in rat primary hepatocytes (2).

    Studies show that exogenous monounsaturated fatty acids inhibit ferroptosis and that this process requires the activation of monounsaturated fatty acids by acyl-CoA synthetase long-chain family member 3 (ACSL3) (3). In addition, studies on a mouse model show that Acsl3 is essential for oleic acid to protect melanoma cells from ferroptosis, which leads to more tumor metastases (4). Furthermore, ACSL3 is required for prostaglandin synthesis and tumorigenesis in non-small cell lung cancer (NSCLC) (5).

    Acyl-CoA synthetase long-chain family member 4 (ACSL4) preferentially catalyzes the formation of arachidonoyl-coenzyme A (AA-CoA) by inserting coenzyme A (CoA) into arachidonic acid (AA) (6). ACSL4-catalyzed acyl-CoAs also participate in the regulation of steroidogenesis (7), eicosanoid biosynthesis (8), and phospholipid remodeling (9). ACSL4 is an essential enzyme for the conversion of two key ferroptosis-inducing signals, oxidized arachidonic and adrenic phosphatidylethanolamines (10,11). Genome-wide CRISPR/Cas9-based genetic screens have demonstrated that ACSL4 is an essential component for ferroptosis execution (11), and genetic or pharmacological inhibition of ACSL4 can initiate a specific anti-ferroptotic rescue pathway (10). ACSL4 expression is upregulated in ferroptosis-sensitive cancer cells compared with ferroptosis-resistant cells (12) and has been shown to predict sensitivity to ferroptosis in a panel of basal-like breast cancer cell lines (11). Moreover, high ACSL4 protein expression in hepatocellular carcinoma (HCC) clinical tissue specimens is associated with improved patient outcomes after sorafenib treatment and could serve as a predictive biomarker (13).

    LPCAT1 (lysophosphatidylcholine acyltransferase 1), an enzyme that functions in phospholipid metabolism and remodeling, has been reported to be highly expressed and to play a tumor-promoting role in multiple human cancers. Overexpression of LPCAT1 is linked to poor prognosis in breast cancer and hepatocellular carcinoma (HCC) (14,15). In cervical cancer, knockdown of LPCAT1 reduces proliferation, migration, and invasion of cancer cells, and LPCAT1 deletion reduces tumor growth and metastasis in mice through Jak2/Stat3 signaling (16). In endometrial cancer, LPCAT1 enhances stemness and metastasis through TGF-β signaling (17). In NSCLC, LPCAT1 upregulates EGFR/PI3K/Akt signaling, promoting resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) (18).

    LPCAT3 (lysophosphatidylcholine acyltransferase 3), also called MBOAT5, is part of the LPCAT family that plays an important role in lipid metabolism (19,20). Elevated expression of LPCAT3 is associated with the iron-dependent cell death process of ferroptosis, characterized by an increase in lipid peroxidation (21). LPCAT3 inhibitors have shown a partial protection from ferroptosis (22).

    Sterol regulatory element–binding proteins (SREBPs) are basic helix-loop-helix–leucine zipper (bHLH-Zip) transcription factors (23,24). Studies show that SREBP-1-dependent fatty acid homeostasis has a critical role in promoting the pro-tumor phenotype of M2-like tumor-associated macrophages (TAMs), and inhibition of SREBP-1 enhances the efficacy of immune checkpoint blockade (25). In addition, suppression of cholesterol biosynthesis by statins stimulates SREBP-1 activation and, therefore, induces TGF-β signaling, promoting the epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma (26).
    1. Mashek, D.G. et al. (2004) J Lipid Res 45, 1958-61.
    2. Li, L.O. et al. (2006) J Biol Chem 281, 37246-55.
    3. Magtanong, L. et al. (2019) Cell Chem Biol 26, 420-432.e9.
    4. Ubellacker, J.M. et al. (2020) Nature 585, 113-118.
    5. Saliakoura, M. et al. (2020) Oncogene 39, 2948-2960.
    6. Quan, J. et al. (2021) Eur J Pharmacol 909, 174397.
    7. Cornejo Maciel, F. et al. (2005) J Mol Endocrinol 34, 655-66.
    8. Kuwata, H. et al. (2014) Biochim Biophys Acta 1841, 44-53.
    9. Killion, E.A. et al. (2018) Mol Metab 9, 43-56.
    10. Kagan, V.E. et al. (2017) Nat Chem Biol 13, 81-90.
    11. Doll, S. et al. (2017) Nat Chem Biol 13, 91-98.
    12. Yuan, H. et al. (2016) Biochem Biophys Res Commun 478, 1338-43.
    13. Feng, J. et al. (2021) Acta Pharmacol Sin 42, 160-170.
    14. Lebok, P. et al. (2019) Aging (Albany NY) 11, 7796-7804.
    15. He, R.Q. et al. (2021) Cancer Cell Int 21, 442.
    16. Gao, F. et al. (2022) Exp Cell Res 421, 113360.
    17. Zhao, T. et al. (2022) Acta Biochim Biophys Sin (Shanghai) 54, 904-916.
    18. Ding, J. et al. (2022) J Cancer 13, 1837-1847.
    19. Matsuda, S. et al. (2008) Genes Cells 13, 879-88.
    20. Zhao, Y. et al. (2008) J Biol Chem 283, 8258-65.
    21. Lee, J.Y. et al. (2021) Biology (Basel) 10, 184. doi: 10.3390/biology10030184.
    22. Reed, A. et al. (2022) ACS Chem Biol 17, 1607-1618.
    23. Brown, M.S. and Goldstein, J.L. (1997) Cell 89, 331-40.
    24. Horton, J.D. et al. (2002) J Clin Invest 109, 1125-31.
    25. Liu, C. et al. (2019) Immunity 51, 381-397.e6.
    26. Gabitova-Cornell, L. et al. (2020) Cancer Cell 38, 567-583.e11.

    Database Links

    UniProt ID: P33121 , Q8NF37 , P36956 , O95573 , Q6P1A2 , O60488


    Entrez-Gene Id: 2180 , 79888 , 6720 , 2181 , 10162 , 2182


    Limited Uses

    Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

    Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.